Belén Garijo Named CEO of Sanofi, Marking a Milestone in Pharma Leadership

Paris, France – In a significant leadership transition, Sanofi has announced the appointment of Belén Garijo as its new Chief Executive Officer, effective April 29, 2026. Garijo, who previously served as CEO and Chair of the Executive Board at Merck KGaA, will succeed Paul Hudson following the upcoming annual general meeting.

Belén Garijo has been a transformative figure in the pharmaceutical sector, renowned for her strategic prowess and deep understanding of research and development. During her tenure at Merck KGaA, Garijo successfully spearheaded initiatives that revitalized the company's innovation pipeline and expanded its global footprint. Her leadership has been marked by a commitment to advancing medical breakthroughs and enhancing operational efficiencies, qualities that she will now bring to Sanofi.

Sanofi, a global leader in the pharmaceutical and biopharmaceutical industry, is set to benefit from Garijo's extensive expertise. The company, known for its focus on developing innovative therapies and vaccines, stands at a pivotal moment as it seeks to bolster its R&D capabilities and enhance its market competitiveness. Garijo's appointment is anticipated to invigorate Sanofi's strategic execution, aligning with its mission to deliver transformative health solutions worldwide.

This appointment is not only a strategic move for Sanofi but also a significant milestone for gender diversity in executive leadership. The pharmaceutical industry, traditionally male-dominated, is seeing a gradual shift as more women assume C-level positions. Garijo's new role at Sanofi marks a notable advancement for female executives, reinforcing the importance of diverse leadership in driving innovation and success.

As Garijo prepares to take the helm, industry analysts and stakeholders alike are optimistic about the fresh perspective and experienced leadership she brings to Sanofi. Her track record of fostering innovation and her dedication to corporate responsibility are expected to steer Sanofi into a new era of growth and sustainability.

Garijo's appointment is a testament to her exemplary career and the broader progress being made towards gender parity in the upper echelons of the pharmaceutical industry. Her leadership is poised to inspire a new generation of women in tech and biopharma, underscoring the growing impact of diverse leadership in shaping the future of healthcare.